Stock Events

Stock Events

ETHZilla

$0.009000

120

-$0.02-71.96% Wednesday 21:00

+$0.00+22.22%Wednesday 23:28Pre-market

Statistics

Day High

0.03

Day Low

0.0058

52W High

0.03

52W Low

0.0058

Volume

1,191,169

Avg. Volume

-

Mkt Cap

0

P/E Ratio

-

Dividend Yield

-

Dividend

-

Earnings

25FebExpected

Q2 2024

Q2 2025

Q3 2025

Q4 2025

999

333

-333

-999

Expected EPS

N/A

Actual EPS

N/A

Financials

-Profit Margin

Unprofitable

2019

2020

2021

2022

2023

2024

0Revenue

-14.18MNet Income

Analyst Ratings

9.00Average Price Target

The highest estimate is 9.00.
From 1 ratings within the last 6 months. This is not an investment recommendation.

Buy

0%

Hold

100%

Sell

0%

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.

CRISPR Therapeutics

CRISPR Therapeutics is involved in gene editing, a cutting-edge area of biotechnology that could compete with 180 Life Sciences' novel therapeutic approaches.

Editas Medicine

Editas Medicine operates in the genome editing space, directly competing with 180 Life Sciences in developing treatments for diseases with unmet medical needs.

Intellia Therapeutics

Intellia Therapeutics is another key player in the CRISPR/Cas9 technology sector, potentially competing with 180 Life Sciences in the field of genetic and autoimmune diseases.

Vertex Pharmaceuticals

Vertex Pharmaceuticals focuses on creating transformative medicines for people with serious diseases, which aligns with 180 Life Sciences' mission, making them competitors.

Regeneron Pharmaceuticals

Regeneron Pharmaceuticals is known for its innovation in biotechnology, competing with 180 Life Sciences in developing novel therapeutics for various diseases.

Alnylam Pharmaceuticals

Alnylam Pharmaceuticals is a leader in RNAi therapeutics, competing with 180 Life Sciences in the development of novel treatments for genetic and other diseases.

Biomarin Pharmaceutical

BioMarin Pharmaceutical focuses on enzyme replacement therapies and other innovative treatments for rare genetic diseases, competing with 180 Life Sciences in the rare disease space.

Sarepta Therapeutics

Sarepta Therapeutics is focused on the discovery and development of RNA-based therapeutics, competing with 180 Life Sciences in the development of innovative treatments for diseases.

About

ETHZilla operates in digital asset management, gaming, and entertainment. The Company is developing an Ether (ETH) accumulation vehicle to serve as a benchmark for on-chain treasury management among public companies, supported by Electric Capital and a DeFi Council of industry experts. Its strategy targets yield generation beyond traditional ETH staking while advancing gaming initiatives and pursuing monetization of legacy biotechnology assets from its origins as a biotech company.

Show more...

CEO

Mr. McAndrew Rudisill BA(Econ)

Employees

4

Country

United States

Listings

0 Comments

Share your thoughts

FAQ

What is ETHZilla stock price today?▼

The current price of ETHZW is $0.01 USD — it has decreased by -71.96% in the past 24 hours. Watch ETHZilla stock price performance more closely on the chart.

What is ETHZilla stock ticker?▼

Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange ETHZilla stocks are traded under the ticker ETHZW.

Is ETHZilla stock price growing?▼

ETHZW stock has risen by +0% compared to the previous week, the month change is a +0% rise, over the last year ETHZilla has showed a -95.01% decrease.

What is ETHZilla revenue for the last year?▼

ETHZilla revenue for the last year amounts to 0 USD.

What is ETHZilla net income for the last year?▼

ETHZW net income for the last year is -14.18M USD.

How many employees does ETHZilla have?▼

As of September 07, 2026, the company has 4 employees.

In which sector is ETHZilla located?▼

ETHZilla operates in the Other sector.

When did ETHZilla complete a stock split?▼

ETHZilla has not had any recent stock splits.

Where is ETHZilla headquartered?▼

ETHZilla is headquartered in Palm Beach, United States.